Patrice Matchaba
Overview
Explore the profile of Patrice Matchaba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farkouh M, Verheugt F, Ruland S, Kirshner H, Jeger R, Gitton X, et al.
J Clin Hypertens (Greenwich)
. 2008 Sep;
10(8):592-602.
PMID: 18772641
The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs...
2.
Hawkey C, Weinstein W, Smalley W, Gitton X, Sallstig P, Stricker K, et al.
Gastroenterology
. 2007 Jul;
133(1):57-64.
PMID: 17631131
Background & Aims: Selective cyclooxygenase-2 inhibitors were developed to reduce the gastrointestinal risk associated with nonsteroidal anti-inflammatory drugs (NSAIDs). The Therapeutic Arthritis Research and Gastrointestinal Event Trial was the largest...
3.
Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan V, Olson M, et al.
Clin Ther
. 2005 Oct;
27(8):1196-214.
PMID: 16199245
Background: The cardiovascular (CV) safety of non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors has been the subject of considerable debate. Objective: The objective of this study was to determine...
4.
Farkouh M, Kirshner H, Harrington R, Ruland S, Verheugt F, Schnitzer T, et al.
Lancet
. 2004 Aug;
364(9435):675-84.
PMID: 15325832
Background: The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal...
5.
Schnitzer T, Burmester G, Mysler E, Hochberg M, Doherty M, Ehrsam E, et al.
Lancet
. 2004 Aug;
364(9435):665-74.
PMID: 15325831
Background: Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events has been...